News and Press Releases
Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers
27 January 2026 -- Illinois, US -- Tempus AI, Inc, a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 27, 2026
ConcertAI and Foundation Medicine Integrate Genomic and Clinical Data to Transform Translational Research and Efficient Drug Development
ConcertAI now offers industry’s most comprehensive clinically-linked dataset to life science organizations Dataset encompasses ConcertAI’s full network of industry partners, representing nearly half a million patients Applications span entire drug...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: January 12, 2026
Fibrocor Therapeutics appoints world-leading nephrologists to Clinical Advisory Board with a focus on its lead indication Alport Syndrome
Fibrocor Therapeutics strengthens its clinical strategy with the appointment of four world-leading nephrology and genetics experts to its Clinical Advisory Board (CAB), reinforcing its scientific leadership in Alport Syndrome The...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: December 9, 2025
661 University Ave, Suite 1300 Toronto, Ontario Canada M5G 0B7
Groundbreaking myalgic encephalomyelitis study identifies over 250 core genes, shared biology with long COVID, and dozens of drug repurposing opportunities
The study reinforces that ME is a complex multisystemic condition with a clear genetic basis and lays the foundation for future clinical trials that could be faster to recruit and...
Category: BioManufacturing, Clinical Trials, Other, Pharmaceutical
Posted: December 4, 2025
Wakam and the FondaMental Foundation create the Precision Mind Award to support Franco-British research on biomarkers in psychiatry
4 November 2025 -- Paris, France -- Following the signing of the Franco-British consortium agreement on biomarkers in psychiatry at the French Embassy in London on 27th October 2025, Wakam...
Category: Drug Discovery, Other, Pharmaceutical
Posted: November 4, 2025
Hôpital Albert Chenevier, Pôle de Psychiatrie 40, rue de Mesly 94000 Créteil, France
Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation
14 October 2025 -- New Jersey, US -- Tonix Pharmaceuticals Holding Corp, a fully integrated biotechnology company with marketed products and a pipeline of development candidates, today announced that Seth...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 14, 2025
Aptamer Group Introduces Novel Biomarker Discovery Service
Accelerated platform delivers validated biomarkers with ready-to-use Optimer ligands in months rather than years Biomarkers are identified based on their ability to translate to drug development strategies. 28 August 2025...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: August 28, 2025
Aptamer group, Suite 2.80 – 2.87, Bio Centre, Innovation Way, Heslington, York, YO10 5NY
PlaqueTec announces positive early research findings from interim analysis in BIOPATTERN trial
Pre-specified interim analysis reveals differences in protein concentration between systemic blood and blood from diseased coronary arteries Safety and functionality data for the updated Liquid Biopsy System supports continuation of...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 6, 2025
Novel Findings Using the Parsortix System Demonstrating Role of CTC:B Cell Clusters in Driving Cancer Progression
Findings may enable the development of novel drugs to target B cell and CTC cluster interactions to suppress cancer metastasis This pivotal work is likely to stimulate further interest in...
Category: Drug Discovery, Other, Pharmaceutical
Posted: February 6, 2025
NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing platform
Findings in lung cancer show that CTCs can provide additional biomarkers not found in ctDNA from single blood sample ANGLE invited to present data at EACR-Illumina webinar on 6 February...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: January 29, 2025
Clinical Trial Powered by Parsortix System Provides First-in-Class Data for Novel Approach to Cancer Treatment
Parsortix system used to identify patients with highly metastatic CTC clusters for targeted treatment New treatment strategy provides ‘uncharted opportunity’ to target metastasis responsible for the vast majority of cancer...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 24, 2025
OGT delivers superior MRD detection capabilities with new SureSeq Myeloid MRD Panel
22 January 2025 – New York City, NY, US – Today, OGT announces the North American launch of its new next-generation sequencing (NGS) SureSeq™ Myeloid MRD Panel, which provides a...
Category: BioManufacturing
Posted: January 23, 2025
Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, UK
Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials
9 January 2025 -- Cambridge, UK and Montreal, Canada -- Biofidelity, a leader in innovative genomic solutions, and CellCarta, the global contract research organization (CRO) partner of choice for biopharmaceutical...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 9, 2025
DNA analysis of Parsortix-enriched CTCs and ctDNA provides complementary information in NSCLC patients treated with AstraZeneca’s osimertinib
The addition of CTC-DNA analysis to clinical trials could identify patients developing treatment resistance prior to disease progression CTC analysis identifies druggable targets which could be used to inform combined...
Category: Biotechnology, Clinical Trials
Posted: November 11, 2024
Publication Demonstrates Potential for Multi-Marker CTC Profiling in Early Prostate Cancer
Parsortix enriched CTCs detected at high rates in localised disease Multi-marker profiling of CTCs could support development of targeted therapies and help stratify patients in clinical trials 17 October 2024...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 17, 2024
